94 related articles for article (PubMed ID: 18163358)
21. Therapeutic potential of new Pt(II) and Ru(III) triazole-pyrimidine complexes against Leishmania donovani.
Magán R; Marín C; Rosales MJ; Salas JM; Sánchez-Moreno M
Pharmacology; 2005 Jan; 73(1):41-8. PubMed ID: 15452362
[TBL] [Abstract][Full Text] [Related]
22. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.
Luque-Ortega JR; Rivas L
Antimicrob Agents Chemother; 2007 Apr; 51(4):1327-32. PubMed ID: 17283192
[TBL] [Abstract][Full Text] [Related]
23. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
24. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis.
Santa-Rita RM; Lira R; Barbosa HS; Urbina JA; de Castro SL
J Antimicrob Chemother; 2005 May; 55(5):780-4. PubMed ID: 15790672
[TBL] [Abstract][Full Text] [Related]
25. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
26. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.
Escobar P; Matu S; Marques C; Croft SL
Acta Trop; 2002 Feb; 81(2):151-7. PubMed ID: 11801222
[TBL] [Abstract][Full Text] [Related]
27. Antileishmanial activity of the ether phospholipid ilmofosine.
Croft SL; Neal RA; Thornton EA; Herrmann DB
Trans R Soc Trop Med Hyg; 1993; 87(2):217-9. PubMed ID: 8337733
[TBL] [Abstract][Full Text] [Related]
28. Momordicatin purified from fruits of Momordica charantia is effective to act as a potent antileishmania agent.
Gupta S; Raychaudhuri B; Banerjee S; Das B; Mukhopadhaya S; Datta SC
Parasitol Int; 2010 Jun; 59(2):192-7. PubMed ID: 20132905
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and anti-leishmanial activity of 1-aryl-β-carboline derivatives against Leishmania donovani.
Gohil VM; Brahmbhatt KG; Loiseau PM; Bhutani KK
Bioorg Med Chem Lett; 2012 Jun; 22(12):3905-7. PubMed ID: 22608390
[TBL] [Abstract][Full Text] [Related]
30. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
[TBL] [Abstract][Full Text] [Related]
31. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.
Ruiter GA; Zerp SF; Bartelink H; van Blitterswijk WJ; Verheij M
Cancer Res; 1999 May; 59(10):2457-63. PubMed ID: 10344758
[TBL] [Abstract][Full Text] [Related]
32. A biochemical and genetic study of Leishmania donovani pyruvate kinase.
Sandoval W; Isea R; Rodriguez E; Ramirez JL
Gene; 2008 Nov; 424(1-2):25-32. PubMed ID: 18725273
[TBL] [Abstract][Full Text] [Related]
33. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.
Wadhone P; Maiti M; Agarwal R; Kamat V; Martin S; Saha B
J Immunol; 2009 Jun; 182(11):7146-54. PubMed ID: 19454711
[TBL] [Abstract][Full Text] [Related]
34. Antiprotozoal activities of phospholipid analogues.
Croft SL; Seifert K; Duchêne M
Mol Biochem Parasitol; 2003 Feb; 126(2):165-72. PubMed ID: 12615315
[TBL] [Abstract][Full Text] [Related]
35. 3D-Quantitative structure-activity relationships of synthetic antileishmanial ring-substituted ether phospholipids.
Kapou A; Benetis NP; Avlonitis N; Calogeropoulou T; Koufaki M; Scoulica E; Nikolaropoulos SS; Mavromoustakos T
Bioorg Med Chem; 2007 Feb; 15(3):1252-65. PubMed ID: 17158053
[TBL] [Abstract][Full Text] [Related]
36. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.
Imbert L; Ramos RG; Libong D; Abreu S; Loiseau PM; Chaminade P
Anal Bioanal Chem; 2012 Jan; 402(3):1169-82. PubMed ID: 22065347
[TBL] [Abstract][Full Text] [Related]
37. Antileishmanial ring-substituted ether phospholipids.
Avlonitis N; Lekka E; Detsi A; Koufaki M; Calogeropoulou T; Scoulica E; Siapi E; Kyrikou I; Mavromoustakos T; Tsotinis A; Grdadolnik SG; Makriyannis A
J Med Chem; 2003 Feb; 46(5):755-67. PubMed ID: 12593656
[TBL] [Abstract][Full Text] [Related]
38. Expression of a PTS2-truncated hexokinase produces glucose toxicity in Leishmania donovani.
Kumar R; Gupta S; Srivastava R; Sahasrabuddhe AA; Gupta CM
Mol Biochem Parasitol; 2010 Mar; 170(1):41-4. PubMed ID: 19925831
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity and biochemical effectiveness of new organometallic complexes of osmium(III) against Leishmania donovani and Trypanosoma cruzi.
Castilla JJ; Mesa-Valle CM; Sanchez-Moreno M; Arnedo T; Rosales MJ; Mascaro C; Craciunescu D; Osuna A
Arzneimittelforschung; 1996 Oct; 46(10):990-6. PubMed ID: 8931894
[TBL] [Abstract][Full Text] [Related]
40. Crucial role of cytosolic tryparedoxin peroxidase in Leishmania donovani survival, drug response and virulence.
Iyer JP; Kaprakkaden A; Choudhary ML; Shaha C
Mol Microbiol; 2008 Apr; 68(2):372-91. PubMed ID: 18312262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
